Literature DB >> 8356248

What is the natural history of rheumatoid arthritis?

T Pincus1, L F Callahan.   

Abstract

Analyses of the natural history of RA, recognizing that all patients receive therapies, indicate the following: 1. Classification criteria for RA identify individuals with (at least) three different types of pathogenetic processes and long-term outcomes; most patients seen in clinical settings have progressive disease. 2. Results of therapies documented to be efficacious in clinical trials are not applicable to the long-term course of RA, in part due to patient selection and the short-time frame of observation in clinical trials; most therapies for RA are not effective in most patients over long periods. 3. Over periods of 10 years or longer, most patients with RA experience radiographic progression and severe functional declines, and work disability is seen in 60% of patients after 10 years of disease. 4. Mortality rates are increased in patients with RA, although RA is generally not listed on death certificates. 5. Individual patients with RA who are at risk for early mortality may be identified through clinical markers, including many involved joints, comorbid cardiovascular disease, and poor functional status according to questionnaires and physical measures. 6. Patient behaviors and lifestyles identified through formal educational level as a marker appear of great importance in the prevalence, morbidity, and mortality of RA.

Entities:  

Mesh:

Year:  1993        PMID: 8356248

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  31 in total

Review 1.  Stem cell transplantation for autoimmune diseases.

Authors:  J Moore; P Brooks
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

4.  Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.

Authors:  J van Aken; L R Lard; S le Cessie; J M W Hazes; F C Breedveld; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

Review 5.  The management of pain in arthritis and the use of cyclooxygenase-2 inhibitors: new paradigms and insights.

Authors:  Edgar Ross
Journal:  Curr Pain Headache Rep       Date:  2004-12

Review 6.  Rheumatoid arthritis: what has changed?

Authors:  Edith Villeneuve; Paul Emery
Journal:  Skeletal Radiol       Date:  2009-02       Impact factor: 2.199

7.  Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Authors:  Adel Gomaa; Mohsen Elshenawy; Noha Afifi; Eman Mohammed; Romany Thabit
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

8.  Outcome of late-onset rheumatoid arthritis.

Authors:  Jaime Calvo-Alén; Alfonso Corrales; Sagrario Sánchez-Andrada; Maria Antonia Fernández-Echevarría; Jose L Peña; Vicente Rodríguez-Valverde
Journal:  Clin Rheumatol       Date:  2005-03-05       Impact factor: 2.980

9.  Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.

Authors:  Andrew M Briggs; Lyn March; Marissa Lassere; Christopher Reid; Lyndall Henderson; Bridie Murphy; Rosemarie van den Haak; Adam Rischin; Margaret Staples; Rachelle Buchbinder
Journal:  Int J Rheumatol       Date:  2009-09-01

10.  Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy.

Authors:  T Möttönen; L Paimela; M Leirisalo-Repo; H Kautiainen; J Ilonen; P Hannonen
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.